王陶陶  

            王陶陶 副主任药师/副研究员

             医学博士，博士研究生导师

西安交通大学第一附属医院药学部 临床药师

2014/09 – 2016/12，西安交通大学，药学院，博士，药物分析学

2011/09 – 2013/07，西安交通大学，药学院，硕士，药剂学

2007/09 – 2011/07，山西医科大学，药学院，学士，药学

中国药理学会治疗药物监测青委会副主任委员；中国药理学会定量药理专业委员会委员；中国药理学会临床药理专业委员会委员；陕西省药学会青年委员会副主任委员；陕西省保健学会感染病防治专业委员会常务委员；陕西省药学会药物分析专业委员会委员；陕西省疾控科普专家。

西安交通大学第一附属医院医院药学部科研实力雄厚、科研条件完善，具备药物分析仪器室、细胞室、粪菌移植实验室、肿瘤药敏实验室等；具备精准用药领域相关的软件、硬件设备，如用于定理药理学分析的NONMEM软件、QSP 套装，具备药物分析的高效液相色谱-质谱联用仪、二维液相色谱、快速血药浓度监测仪器等。课题组在治疗药物监测、药物基因组学、群体药动学、生理药动学、代谢组学、卫生技术评估等方面具备丰富的研究经验与示范性研究体系。同时致力于将人工智能、新型药物浓度监测方法（如电化学分析法）等用于解决精准用药领域中的问题。欢迎对精准用药相关方向感兴趣的同学联系报考或前来实习。

研究领域为定量药理学与精准用药，及个体化用药软件与药物检测新方法的研发；在感染性疾病精准用药方面具有丰富的临床经验。

主持的项目基金

1. 基于分布、清除机制引导水溶性抗菌药物在脓毒症CRRT患者中精准用药体系的构建，国家自然科学基金面上项目，82474003，2025.1-2028.12，48万，主持。
2. 基于靶细胞PK/PD模型研究伏立康唑预防侵袭性曲霉菌病的机制及给药方案优化，国家自然科学基金青年项目，81703618，2018.1-2020.12，20.1万，主持。
3. 基于MOF@AuNPs复合物的表面增强拉曼基底构建抗菌药物TDM体系及应用，陕西省重点研发计划一般项目，2024SF-YBXM-275，6万，2024.1-2025.12，主持。
4. 基于生理药动学和群体药动学模型指导伏立康唑在肝硬化患者中的给药方案优化和个体化用药决策，陕西省重点研发计划一般项目，2020SF-064，8万，2020.1-2021.12，主持。​​​​​​​

发明专利

1. 王陶陶，董亚琳，王楚慧，陈思颖，孙金钥，王光启，曾卫东。一种个体化用药调整剂量的自动确定方法及系统。2025年04月11日，中国，ZL202510112928.7。
2. 王陶陶，董亚琳，孙金钥，王楚慧，陈思颖，杜倩，​​​​​​​曾卫东，王光启。个体化用药血药浓度预测算法的辅助生成方法及系统。2025年08月12日，中国，ZL202510366033.6。

代表性论著

1. Jiaojiao Chen, Quanfang Wang, Sihan Li, Ruiying Han, Chuhui Wang, Shiqi Cheng, Baogui Yang, Lizhuo Diao, Tingting Yang, Dan Sun, Di Zhang, Yalin Dong*, Taotao Wang*. Does Two-Step Infusion Improve the Pharmacokinetics/Pharmacodynamics Target Attainment of Meropenem in Critically Ill Patients? J Pharm Sci. 2024;113(9):2904-2914.
2. Quanfang Wang, Yuefeng Sun, Shidi Zhao, Chuqi Bai, Zhiwei Cong, Yalin Dong, Taotao Wang. Metallo-β-lactamases immobilized by magnetic zeolitic imidazolate frameworks-8 for degradation of β-lactam antibiotics in an aqueous environment. RSC Adv. 2023;13(49):34884-34890.
3. Quanfang Wang, Sihan Li, Jiaojiao Chen, Luting Yang, Yulan Qiu, Qian Du, Chuhui Wang, Mengmeng Teng, Taotao Wang*, Yalin Dong*. A novel strategy for therapeutic drug monitoring: application of biosensors to quantify antimicrobials in biological matrices. J Antimicrob Chemother,2023,78:(11):2612-2629.
4. Taotao Wang^#, Liyan Miao^#, Hua Shao, Xiaohua Wei, Miao Yan, Xiaocong Zuo, Jun Zhang, Xin Hai, Guangjun Fan, Wei Wang, Linlin Hu, Jian Zhou, Yichang Zhao, Yueliang Xie, Jingjing Wang, Sixun Guo, Liu Jin, Hao Li, Hui Liu, Quanfang Wang, Jiaojiao Chen, Sihan Li, Yalin Dong*. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study. Int J Antimicrob Agents, 2022;60(5-6):106692.
5. Chen Jiaojiao, Li Sihan, Wang Quanfang, Wang Chuhui, Qiu Yulan, Yang Luting, Han Ruiying, Du Qian, Chen Lei, Dong Yalin*, Wang Taotao*. Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy. Pharmaceutics, 2022, 14(4), 842.
6. Yuzhu Dong, Dan Sun, Yan Wang, Qian Du, Ying Zhang, Ruiying Han, Mengmeng Teng, Tao Zhang, Lei Shi, Gezhi Zheng, Yalin Dong*, Taotao Wang*. Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure. BMC Infect Dis. 2022;22(1):23.
7. Taotao Wang, Miao Yan, Dan Tang, Yuzhu Dong, Li Zhu, Qian Du, Dan Sun, Jianfeng Xing, Yalin Dong*. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis. Pharmacotherapy. 2021;41(2):172-183.
8. Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong*, Taotao Wang*. Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients. Antibiotics (Basel). 2021;10(8):993.
9. Dong Yuzhu, Li Ying, Zhang Ying, Sun Dan, Du Qian, Zhang Tao, Teng Mengmeng, Han Ruiying, Wang Yan, Zhu Li, Lei Jin’e, Dong Yalin*, Wang taotao*. Clinical Efficacy and Cost-Effectiveness of beta-Lactam/beta-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection. Infection and drug resistance. 2020; 13:1327-1338.
10. Dong YZ, Li Y, Zhang Y, Zhang T, Zhu L, Dong YL*, Wang TT*. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment. Basic Clin Pharmacol Toxicol. 2019;125(4):353-359.
11. Wang TT, Yan M, Tang D, Xue L, Zhang T, Dong YZ, Zhu L, Wang XG, Dong YL*. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis. J Clin Pharm Ther, 2018; 43(6):849-854.
12. 王陶陶, 胡萨萨, 尤海生, 陈思颖, 陈丽梅, 董海燕, 董亚琳*. 恶性血液病患者中伏立康唑血药浓度监测及其影响因素的探讨. 中国医院药学杂志, 2018; 38(7): 693-696+707.
13. 王陶陶, 陈思颖, 尤海生, 董海燕, 王雪, 董亚琳*. 侵袭性真菌感染患者伏立康唑肝毒性的研究. 中国药学杂志, 2018; 53(4): 290-294.
14. Lei JE, Xu JR*, Wang TT*. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study. J Mycol Med, 2018; 28(2): 310-313. (IF=1.606)
15. You HS, Dong YZ, Zou YM, Zhang T, Lei JE, Chen LM, Wang X, Dong YL, Wang TT*. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations. Int J Clin Pharmacol Ther, 2018; 56(5): 239-246.
16. Wang TT, Zhang T, Meng T, Li Y, Chen L, Yang QT, Dong HY, Lei JE, Chen LM, Dong YL*. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model. J Transl Med, 2018; 16(1): 157.
17. Wang TT, Yan M, Tang D, Xue L, Zhang T, Dong YZ, Zhu L, Wang XG, Dong YL*. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh Class B and C Cirrhosis: a multicenter study. Int J Infect Dis, 2018; 72:49-54.
18. Wang TT, Yang QT, Wang Y, Li Y, Meng T, Chen L, Xie J, Xing JF, Dong YL*. Determination and characterization of the uptake of voriconazole in human lung epithelial cells by high-performance liquid chromatography-tandem mass spectrometry. Analytical Letters, 2017; 50(2): 304-314.
19. Wang TT, Yang QT, Chen L, Li Y, Meng T, Wang Y, Zhang T, Lei JE, Xing JF, Dong YL*. Uptake and efflux kinetics, and intracellular activity of voriconazole against A. fumigatus in human pulmonary epithelial cells: a new application for preventing invasive pulmonary aspergillosis[J]. Fundam Clin Pharmacol, 2017; 31(3): 311-318.
20. Wang TT, Xie J, Wang Y, Zheng XW, Lei JE, Wang X, Dong HY, Yang QT, Chen L, Xing JF, Dong YL*. Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections. Pharmacotherapy, 2015; 35(9): 797-804.
21. Wang TT, Li N, Hu SS, Xie J, Lei JE, Wang Y, Zheng XW, Xing JF, Dong YL*. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections. Int J Clin Pharmacol Ther, 2015; 53(5):356-362.
22. 王陶陶, 孙金钥, 陈思颖, 蔡江霞, 程晓亮, 王雪, 董海燕, 董亚琳*. 侵袭性真菌感染患者伏立康唑群体药动学研究及给药方案优化.中国药学杂志, 2014; 49(3):227-233.
23. Wang TT^#, Chen SY^#, Sun JY, Cai JX, Cheng XL, Dong HY, Wang X, Xing JF, Dong WH, Yao HP, Dong YL*. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother, 2014; 69(2): 463-470.​​​​​​​
24. Wang TT, Zhu HF, Sun JY, Cheng XL, Xie J, Dong HY, Chen LM, Wang X, Xing JF*, Dong YL*. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents, 2014; 44(5): 436-442.